Figure 3.

A

Treatment up to week 12, 16 posttreatment follow-up visit; no significant difference observed between maraviroc and placebo treatment groups at any time point; error bars represent SEM.

B

No significant difference observed between maraviroc and placebo treatment groups at any time point; error bars represent SEM.

C

Treatment up to week 12, 16 posttreatment follow-up visit; no significant difference observed between maraviroc and placebo treatment groups at any time point; error bars represent SEM. ACR20 = American College of Rheumatology 20; BID = twice daily; CRP = C-reactive protein; DAS = disease activity score; FAS = full analysis set; LUCF = last observation carried forward; SEM = standard error of the mean.